Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor
暂无分享,去创建一个
V. Fuster | J. Badimón | D. Shimbo | J. Osende | S. Kunitada | Y. Shimoto | Julie L. Chen | J. Robbins
[1] F. Van de Werf,et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. , 2001, European heart journal.
[2] E. Antman,et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. , 1999, Circulation.
[3] L. Chi,et al. Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. , 2001, Current opinion in pharmacology.
[4] J. Badimón,et al. Antithrombotic Effect of Tissue Factor Inhibition by Inactivated Factor VIIa: An Ex Vivo Human Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[5] V. Fuster,et al. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivo model of deep arterial injury. , 2000, Thrombosis research.
[6] V. Fuster,et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. , 1999, Circulation.
[7] J. Badimón,et al. Intimal Tissue Factor Activity Is Released from the Arterial Wall after Injury , 2000, Thrombosis and Haemostasis.
[8] J. Freyssinet,et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.
[9] J. Badimón,et al. The role of plaque rupture and thrombosis in coronary artery disease. , 2000, Atherosclerosis.
[10] R. Califf,et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. , 1997 .
[11] V. Fuster,et al. Antithrombotic effects of abciximab. , 2000, The American journal of cardiology.
[12] E. Antman,et al. Low-molecular-weight heparins in the treatment of acute coronary syndromes. , 2001, Archives of internal medicine.
[13] J. Badimón,et al. Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] H. Ishihara,et al. DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa , 1994, Thrombosis and Haemostasis.
[15] V. Fuster,et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.
[16] A. Turpie,et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. , 2001, The New England journal of medicine.
[17] K. Kaikita,et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[18] K. Gallagher,et al. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis , 1999, Basic Research in Cardiology.
[19] J. Herbert,et al. Effect of Factor Xa Inhibitors on the Platelet-derived Microparticles Procoagulant Activity In Vitro> and In Vivo in Rats , 2000, Thrombosis and Haemostasis.
[20] H. Asakura,et al. Effects of DX-9065a, an Orally Active, Newly Synthesized and Specific Inhibitor of Factor Xa, against Experimental Disseminated Intravascular Coagulation in Rats , 1994, Thrombosis and Haemostasis.
[21] 副島 弘文. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina , 1999 .
[22] Zahi A Fayad,et al. Acute coronary syndromes: biology , 1999, The Lancet.
[23] V. Fuster,et al. Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[24] J. Cairns,et al. Antithrombotic agents in coronary artery disease. , 1995, Chest.
[25] V. Hasselblad,et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation , 2002, Circulation.